Analyzing Arca Biopharma (ABIO) and Lantheus (LNTH)

Share on StockTwits

Arca Biopharma (NASDAQ:ABIO) and Lantheus (NASDAQ:LNTH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings for Arca Biopharma and Lantheus, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arca Biopharma 0 0 0 0 N/A
Lantheus 0 1 1 0 2.50

Lantheus has a consensus price target of $20.50, indicating a potential downside of 13.21%. Given Lantheus’ higher possible upside, analysts clearly believe Lantheus is more favorable than Arca Biopharma.

Risk & Volatility

Arca Biopharma has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Earnings & Valuation

This table compares Arca Biopharma and Lantheus’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arca Biopharma N/A N/A -$7.93 million N/A N/A
Lantheus $343.37 million 2.65 $40.51 million $0.94 25.13

Lantheus has higher revenue and earnings than Arca Biopharma.

Institutional and Insider Ownership

11.3% of Arca Biopharma shares are owned by institutional investors. Comparatively, 93.3% of Lantheus shares are owned by institutional investors. 3.6% of Arca Biopharma shares are owned by insiders. Comparatively, 1.2% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Arca Biopharma and Lantheus’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Arca Biopharma N/A -94.63% -83.28%
Lantheus 11.80% 73.07% 9.02%

Summary

Lantheus beats Arca Biopharma on 8 of the 10 factors compared between the two stocks.

About Arca Biopharma

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. The company's lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in chronic heart failure patients with reduced left ventricular ejection fraction. It also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as peripheral arterial disease and chronic heart failure. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

About Lantheus

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, an ultrasound contrast agent used in ultrasound exams of the heart; TechneLite, a technetium generator that provides the essential nuclear material used in nuclear medicine procedures; and Xenon, a radiopharmaceutical gas used to assess pulmonary function and imaging cerebral blood flow. The company also offers Neurolite, an injectable that is used to identify the area in the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable technetium-labeled imaging agent used in myocardial perfusion imaging (MPI) procedures that assess blood flow distribution to the heart. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium Tl 201 that is used in MPI studies to detect cardiovascular disease; Gallium Ga 67, which is used to detect various infections and cancerous tumors; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Quadramet, a therapeutic product, which is used to treat severe bone pain associated with metastatic bone lesions. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; LMI 1195 that has completed Phase I clinical trials for assessing cardiac sympathetic nerve function; and LMI 1174, which is in pre-clinical development targeted to elastin in the arterial walls and atherosclerotic plaque. The company sells its products to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and radiopharmacies. Lantheus Holdings, Inc. was founded in 1956 and is headquartered in North Billerica, Massachusetts.

Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analyzing Arca Biopharma  and Lantheus
Analyzing Arca Biopharma and Lantheus
Qutoutiao  vs. Its Competitors Financial Comparison
Qutoutiao vs. Its Competitors Financial Comparison
$0.26 Earnings Per Share Expected for Ship Finance International Limited  This Quarter
$0.26 Earnings Per Share Expected for Ship Finance International Limited This Quarter
Caleres  Stock Price Down 8.7% Following Weak Earnings
Caleres Stock Price Down 8.7% Following Weak Earnings
Credit Suisse Group Analysts Give HeidelbergCement  a €74.00 Price Target
Credit Suisse Group Analysts Give HeidelbergCement a €74.00 Price Target
Jungheinrich  Given a €25.00 Price Target by Kepler Capital Markets Analysts
Jungheinrich Given a €25.00 Price Target by Kepler Capital Markets Analysts


© 2006-2019 Ticker Report